Cost-effectiveness analysis of early versus non-early intervention in acute migraine based on evidence from the 'Act when mild' study

Applied Health Economics and Health Policy

Volumn 10, Issue 3, 2012, Pages 201-215

  Slof, John ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Almotriptan; Cost effectiveness; Cost utility; Intervention; Migraine

Indexed keywords

ALMOTRIPTAN; PLACEBO;

ADULT; ARTICLE; BOOTSTRAPPING; CLINICAL ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COST; EARLY INTERVENTION; ECONOMIC EVALUATION; FEMALE; HUMAN; MALE; MEDICAL SOCIETY; MIGRAINE; NON EARLY INTERVENTION; PAIN ASSESSMENT; PATIENT CODING; PROBABILITY; PROSPECTIVE PAYMENT; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ACUTE DISEASE; COST-BENEFIT ANALYSIS; EARLY MEDICAL INTERVENTION; FRANCE; HUMANS; MIGRAINE DISORDERS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN RECEPTOR AGONISTS; TRYPTAMINES;

EID: 84859982625     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11630890-000000000-00000     Document Type: Article

References (55)

1. World Health Organization. The global burden of disease. 2004 update. Geneva, 2008. Available from URL: http:// www.who.int/healthinfo/global-burden- disease/GBD-report-2004update-full.pdf [Accessed 2011 Jan 4]
2. Sheffield RE. Migraine prevalence: a literature review. Headache 1998; 38: 595-601 (Pubitemid 28481002)
3. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache 1998; 38: 87-96 (Pubitemid 28155226)
4. Hazard E, Munakata J, Bigal ME, et al. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value Health 2009; 12: 55-64
5. Andlin-Sobocki P, Jodie;hnsson B, Wittchen H, et al. Cost of disorders of the brain in Europe. Eur J Neurol 2005; 12 Suppl. 1: 1-12
6. Lipton RB, Stewart WF, von Korff M. Burden of migraine: societal costs and therapeutic opportunities. Neurology 1997; 48: S4-9 (Pubitemid 27120080)
7. Fishman P, Black L. Indirect costs of migraine in a managed care population. Cephalalgia 1999; 19: 50-7 (Pubitemid 29136852)
8. Lambert J, Carides GW, Meloche JP, et al. Impact of migraine symptoms on health care use and work loss in Canada in patients randomly assigned in a phase III clinical trial. Can J Clin Pharmacol 2002; 9: 158-64 (Pubitemid 35408200)
9. Dahlof CGH. Measuring disability and quality of life. Drugs Today 2003; 39 Suppl. D: 17-23
10. Dodick DW. Acute and prophylactic management of migraine. Clin Cornerstone 2001; 4: 36-52
11. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668-75 (Pubitemid 33124324)
12. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22: 633-58 (Pubitemid 36609333)
13. Evers S, A áfra J, Frese A, et al. EFNS guideline on the drug treatment of migraine- revised report of an EFNS task force. Eur J Neurol 2009; 16: 968-81
14. Goadsby PJ. The Act when Mild (AwM) Study: a step forward in our understanding of early treatment in acute migraine. Cephalalgia 2008; 28 Suppl. 2: 36-41
15. Tfelt-Hansen P, Block G, Dahlodie;f C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20: 765-86 (Pubitemid 32154559)
16. Cady RK, Sheftell F, Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 2000; 22: 1035-48
17. Pascual J, Laáinez JM, Leira R, et al. Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study. Neurologia 2003; 18: 7-17
18. Laáinez MJ. Clinical benefits of early triptan therapy for migraine. Cephalalgia 2004; 24 Suppl. 2: 24-30
19. Tranche Iparraguirre S, Martiánez Eizaguirre JM, Galvaán Cervera J, et al. Tolerance to almotriptan and its effectiveness in primary care. Aten Primaria 2005; 35: 52-3 (Pubitemid 40293150)
20. Klapper J, Lucas C, Rosjo O, et al. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia 2004; 24: 918-24 (Pubitemid 39471916)
21. Cady R, Martin V, Mauskop A, et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache 2006; 46: 914-24 (Pubitemid 43794743)
22. Lanteári-Minet M, Mick G, Allaf B. Early dosing and efficacy of triptans in acute migraine treatment: The TEMPO study. Cephalalgia. Epub 2012 Jan 10
23. Freitag FG, Finlayson G, Rapoport AM, et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5mg Time Versus IntensityMigraine Study (AIMS).Headache 2007; 47: 519-30 (Pubitemid 46625261)
24. Mathew NT, Finlayson G, Smith TR, et al. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache 2007; 47: 189-98
25. Freitag FG, Smith T, Mathew N, et al. Effect of early intervention with almotriptan vs placebo on migraine associated functional disability: results from the AEGIS Trial. Headache 2008; 48: 341-54 (Pubitemid 351517774)
26. Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. nonearly intervention in acute migraine -Act when Mild (AwM): a double-blind, placebo-controlled trial of almotriptan. Cephalalgia 2008; 28: 383-91 (Pubitemid 351341454)
27. Lanteári-Minet M, Diaz-Insa S, Leone M, et al. Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START study. Int J Clin Pract 2010; 64: 936-43
28. Dodick DW. Applying the benefits of the AwM Study in the clinic. Cephalalgia 2008; 28 Suppl. 2: 42-9
29. Valade D. Early treatment of acute migraine: new evidence of benefits. Cephalalgia 2009; 29 Suppl. 3: 15-21
30. Linde M, Mellberg A, Dahlodie;f C. The natural course of migraine attacks: a prospective analysis of untreated attacks compared with attacks treated with a triptan. Cephalalgia 2006; 26: 712-21
31. El Hasnaoui A, Vray M, Blin P, et al. Assessment of migraine severity using the MIGSEV scale: relationship to migraine features and quality of life. Cephalalgia 2004; 24: 262-70 (Pubitemid 38446166)
32. Ng-Mak DS, Cady R, Chen Y, et al. Can migraineurs accurately identify their headaches as migraine at attack onset? Headache 2007; 47: 645-53 (Pubitemid 46733714)
33. Gendolla A. Early treatment in migraine: how strong is the current evidence? Cephalalgia 2008; 28 Suppl. 2: 28-35
34. Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 2nd edition. Cephalalgia 2004; 24 Suppl. 1: 1-160
35. VIDAL. Fiches meádicaments [online]. Available from URL: http://www.vidal.fr/fiches-medicaments/ [Accessed 2010 Dec 12]
36. EUROSTAT. Hourly labour costs - Nace Rev. 2. [online]. Available from URL: http://epp.eurostat.ec.europa.eu/ portal/page/portal/statistics/search- database#/ [Accessed 2011 Mar 18]
37. Briggs AH,Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6: 327-40 (Pubitemid 27384638)
38. Yu J, Goodman MJ, Oderda GM. Economic evaluation of pharmacotherapy of migraine pain: a review of the literature. J Pain Palliat Care Pharmacother 2009; 23: 396-408
39. Cady RK, Sheftell F, Lipton RB, et al. Economic implications of early treatment of migraine with sumatriptan tablets. Clin Ther 2001; 23: 284-91 (Pubitemid 32231119)
40. Halpern MT, Lipton RB, Cady RK, et al. Costs and outcomes of early versus delayed treatment with sumatriptan. Headache 2002; 42: 984-99 (Pubitemid 35470706)
41. Kwong WJ, Taylor FR, Adelman JU. The effect of early intervention with sumatriptan tablets on migraine-associated productivity loss. J Occup Environ Med 2005; 47: 1167-73 (Pubitemid 41642508)
42. Freitag FG. Pharmacoeconomic benefits of almotriptan in the acute treatment of migraine. Expert Rev Pharmacoeconomics Outcomes Res 2008; 8: 105-10 (Pubitemid 351959540)
43. Martin BC, Pathak DS, Sharfman MI, et al. Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache 2000; 40: 204-15 (Pubitemid 30169885)
44. Wagner TH, Patrick DL, Galer BS, et al. A new instrument to assess the long-term quality of life effects from migraine: development and psychometric testing of the MSQOL. Headache 1996; 36: 484-92 (Pubitemid 26295215)
45. Stewart WF, Lipton RB, Dowson AJ, et al. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 2001; 56 Suppl. 1: S20-8 (Pubitemid 32240082)
46. Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item shortform survey for measuring headache impact: the HIT-6. Qual Life Res 2003; 12: 963-74 (Pubitemid 37386625)
47. Bala MV, Zarkin GA. Are QALYs an appropriate measure for valuing morbidity in acute diseases? Health Econ 2000; 9: 177-80 (Pubitemid 30148164)
48. Evans KW, Boan JA, Evans JL, et al. Economic evaluation of oral sumatriptan compared with caffeine/ergotamine for migraine. Pharmacoeconomics 1997; 12: 565-77 (Pubitemid 27471145)
49. Zhang L, Hay JW. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine. CNS Drugs 2005; 19: 635-42 (Pubitemid 41058373)
50. Slof J, Laáinez JM, Comas A, et al. Almotriptan vs. ergotamine plus caffeine for acute migraine treatment: a costefficacy analysis. Neurologiáa 2009; 24: 147-53
51. Kaplan R, Anderson JP. A general health policy model: update and applications. Health Serv Res 1988; 23: 203-35
52. Ferrari MD. Should we advise patients to treat migraine attacks early? Cephalalgia 2004; 24: 915-7 (Pubitemid 39471915)
53. Bendtsen L, Mattsson P, Zwart J, et al. Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia 2003; 23: 487-90 (Pubitemid 37114968)
54. Jacob-Tacken KH, Koopmanschap MA, Meerding WJ, et al. Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ 2005; 14: 435-43 (Pubitemid 40723852)
55. Brandes JL, Kudrow D, Cady R, et al. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia 2005; 25: 735-42 (Pubitemid 41208315)